Tag Archive for: Optimum Conference

Weekly Roundup: With great power comes a place on the Medicine Maker Power List. Optimum’s clients have the power.

/in

ReBio Pharma appointed leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer ReBio Pharma, a biotechnology company developing novel, targeted, eye- and vision-preserving therapies for ocular oncology, announced the appointment of Professor Mandeep Sagoo, MB, PhD, FRCS (Ed), FRCOphth, as Chief Medical Officer (CMO). In this role, Professor Sagoo will lead ReBio’s clinical and […]

Read more

Weekly Roundup: Transformative tech at ON Helix 2026

/in

Sofinnova Partners announced Myricx Bio agrees to be acquired by Novartis Sofinnova Partners, a leading European life sciences venture capital firm, announced that its portfolio company Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion, including $1.1 billion cash upfront plus potential milestone payments. Sofinnova Partners seeded the […]

Read more

Weekly Roundup: Events, events & more events

/in

Hansa Biopharma’s ConfIdeS Phase 3 abstract selected for ‘What’s Hot, What’s New’ plenary at ATC 2026  Hansa Biopharma AB, announced on Thursday that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” had been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, which took place in Boston on June […]

Read more

Weekly Roundup: Appointments and new perspectives

/in

Hansa Biopharma appointed Adam Cutler as new Chief Financial Officer Hansa Biopharma AB announced the appointment of Adam Cutler as its new Chief Financial Officer (CFO) and member of the Executive Committee, effective June 22, 2026.  Adam succeeds Evan Ballantyne, who has served as CFO since 2024. Evan will continue in the role until June […]

Read more

Weekly Roundup: Exciting clinical stage updates and your LSX Nordic Congress summary

/in

Progress for our clients in the clinic this week, with Mestag Therapeutics dosing the first patient in their STARLYS clinical trial and STORM Therapeutics to present data on its dose escalation study at ASCO later this month. More good news, as Hansa Biopharma entered a multi-million-Euro licensing agreement with SERB S.A. Bring on the bank […]

Read more
© Optimum Strategic Communications.